3 results
Approved WMOCompleted
Primary: (part 3) Potential of BPR277 1% ointment b.i.d. to improve the clinical severity of lesional skin in the majority of NS patients at end of treatment versus baseline of >= 2 points, dose range and regimen relationship on clinical…
Approved WMOCompleted
Primary:To investigate the safety and tolerability of 60 mg 3 times daily doses of GSK2982772 in subjects with moderate to severe ulcerative colitis.Secondary:To assess the preliminary efficacy, biomarkers, histological disease activity, response…
Approved WMOCompleted
To assess the efficacy of secukinumab 300 mg s .c. vs. placebo in patients with overuse rotator cuff tendinopathy in relieving clinical symptoms at week 14